RxDoctor Payments Data

Mahmood Peshimam, MD

Family Medicine · Irvine, CANPI 1801950498

Payments from drug & device makers

$44,090in general payments, 2019–2025

Across 12 payments — averaging $3674.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi Pasteur Inc.$43K
  • GSK$241
  • Merck$224
  • Emergent Biosolutions Inc.$100
  • Pfizer$36
  • Bavarian Nordic A/s$19
$1,500in research payments, 2019–2025

Across 1 payment — averaging $1500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi Pasteur Inc.$2K

What the payments were for

  • Food & beverage$620100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,090 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$67,741
Medicare patients
126
Services billed
643

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ArexvyRsvpref3 Antigen/As01e/Pf12$3,632
Atovaquone-Proguanil HclAtovaquone/Proguanil Hcl43$3,127
Boostrix TdapDiphth,pertuss(Acell),tet Vac14$984
Metformin Hcl63$613
Atorvastatin Calcium90$572
Tamsulosin Hcl42$560
Escitalopram Oxalate26$478
Levothyroxine Sodium26$393
Gabapentin20$388
Pantoprazole Sodium19$384
Azithromycin100$335
Losartan Potassium46$282
Amlodipine Besylate36$253
Omeprazole14$252
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid37$237

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKArexvy$241$3,63212 claims
PfizerPaxlovid$36$017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Irvine

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →